Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study


BACKGROUND In this study, our aim was to identify molecular aberrations predictive for response to everolimus, an mTOR inhibitor, regardless of tumor type. METHODS To generate hypotheses about potential markers for sensitivity to mTOR inhibition, drug sensitivity and genomic profiles of 835 cell lines were analyzed. Subsequently, a multicenter study was… (More)
DOI: 10.18632/oncotarget.16029


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.